Trajectory of Neuroinflammatory Markers in Cerebrospinal Fluid Prior to and After Thoracic Aortic Surgery (TURBO)

March 28, 2023 updated by: Wilson F. Abdo, Radboud University Medical Center

Trajectory of Neuroinflammatory Markers in Cerebrospinal Fluid Prior to and After Thoracic Aortic Surgery: the TURBO Study

Observational prospective pilot study to analyze the trajectory of neuroinflammatory protein expression in cerebrospinal fluid (CSF) in relation to systemic compartment in patients undergoing thoracic aortic surgery.

The aim of this study is to identify and unravel the biochemical (neuroinflammatory) pathways involved in postoperative delirium.

Patient undergoing thoracic aortic surgery will have an external lumbar drain (ELD) in situ on the day before surgery. This ELD remains in place during and three days after surgery to reduce the risk on periprocedural spinal cord ischemia. Paired measurements of CSF and blood will be analyzed.

Study Overview

Detailed Description

Major (cardiovascular) surgery is frequently associated with cerebral dysfunction postoperatively. Major surgical procedures account for substantial systemic inflammatory activation. Interestingly, animal models have shown that surgery rather than anaesthetics trigger a neurocognitive decline. An increase of pro-inflammatory cytokines and activation of immune cells mediate this post operative cognitive decline. There is growing support that systemic inflammation can activate the innate immune system of the brain leading to inflammation in the brain ('neuroinflammation'). This neuroinflammation is suggested to play a pivotal role in postoperative delirium and postoperative cognitive decline due to surgery-related systemic inflammation. However little evidence is available on the extend of the neuroinflammation and which biochemical pathways are dysregulated in the brain after surgery.

Thoracic aortic surgery offers the unique opportunity to study the trajectory of protein expression in CSF prior to and after surgery in a non-invasive matter. It is standard of care that an external lumbar drain (ELD) is placed the day prior to surgery and this ELD will remain in place during three postoperative days.

To advance the understanding of the impact of major surgery to the brain, the investigators wish to study the trajectory of protein expression prior to and after thoracic aortic surgery.

Study Type

Observational

Enrollment (Anticipated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Nijmegen, Netherlands, 6500HB
        • Recruiting
        • Department of Intensive Care Medicine, Radboud university medical center
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Adult patients undergoing thoracic aortic surgery who will therefore receive an external lumbar drain as a standard of care procedure.

Description

Inclusion Criteria:

  • Competent patients ≥ 18 years
  • Patients who will undergo thoracic aortic surgery and will therefore receive an external lumbar drain as a standard of care procedure.

Exclusion Criteria:

  • Patients with meningitis/encephalitis/brain abscess within the last 6 months
  • Patients with other neurological conditions: brain injury (acute stroke, brain trauma or cerebral haemorrhage) within the last 3 months, known brain tumours, neurodegenerative disease or known pre-existing cognitive impairment (to a degree that would be compatible with mild cognitive impairment or more).
  • Brain or spinal surgery within the last 3 months
  • Active infection <2 weeks before surgery
  • Patients who object against storage of their body material for scientific reasons

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Thoracic aortic surgery patients
Kinetics of neuroinflammatory markers in CSF and blood

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Trajectory of the concentration of a panel of inflammatory proteins in CSF
Time Frame: 9 timepoints: Baseline (immediately before surgery); Start extracorporeal circulation; Stop extracorporeal circulation (ECC); 2 hours (h) after stop ECC; 4h after stop ECC; 6h after stop ECC; 24h after baseline; 48h after baseline; 72h after baseline
Changes in CSF cytokine concentrations will be determined (including IL6, IL8, IL10, MCP-1, IL1RA and CX3CL1) between timepoints described below.
9 timepoints: Baseline (immediately before surgery); Start extracorporeal circulation; Stop extracorporeal circulation (ECC); 2 hours (h) after stop ECC; 4h after stop ECC; 6h after stop ECC; 24h after baseline; 48h after baseline; 72h after baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Trajectory of the concentration of a panel of inflammatory proteins in plasma
Time Frame: 9 timepoints: Baseline to 72 hours after surgery
Changes in plasma cytokine concentrations will be determined (including IL6, IL8, IL10, MCP-1, IL1RA and CX3CL1) between timepoints described below.
9 timepoints: Baseline to 72 hours after surgery
Trajectory of blood-CSF barrier disruption based on CSF/Plasma albumine ratio
Time Frame: 9 timepoints: Baseline to 72 hours after surgery
CSF/Plasma albumine ratios will be measured for all timepoints where paired CSF/plasma samples are present
9 timepoints: Baseline to 72 hours after surgery
Occurence of postoperative delirium
Time Frame: 14-day incidence of delirium
Yes or No
14-day incidence of delirium
Trajectory of brain injury markers in CSF
Time Frame: 9 timepoints: Baseline to 72 hours after surgery
Changes in brain injury markers will be determined (including NFL, S100B, GFAP, UCHL1, NSE)
9 timepoints: Baseline to 72 hours after surgery
Trajectory of brain injury markers in plasma
Time Frame: 9 timepoints: Baseline to 72 hours after surgery
Changes in brain injury markers will be determined (including S100B, GFAP, UCHL1, NSE)
9 timepoints: Baseline to 72 hours after surgery
Changes in ex vivo cytokine production after whole blood stimulation
Time Frame: 5 timepoints: Baseline to 48 hours after surgery
TNF-a,IL6, IL10
5 timepoints: Baseline to 48 hours after surgery
Changes in mHLA-DR expression
Time Frame: 5 timepoints: Baseline to 48 hours after surgery
monocytic HLA-DR expression assessed by flowcytometry
5 timepoints: Baseline to 48 hours after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 18, 2017

Primary Completion (Anticipated)

December 1, 2025

Study Completion (Anticipated)

December 1, 2026

Study Registration Dates

First Submitted

May 6, 2019

First Submitted That Met QC Criteria

August 19, 2020

First Posted (Actual)

August 24, 2020

Study Record Updates

Last Update Posted (Actual)

March 31, 2023

Last Update Submitted That Met QC Criteria

March 28, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Postoperative Delirium

Clinical Trials on Trajectory of neuroinflammatory proteins in CSF and blood

3
Subscribe